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Background: Postoperative surgical site infections cause substantial morbidity, prolonged hospitalization, costs
and even mortality and remain one of the most frequent surgical complications. Approximately 14% to 30% of all
patients undergoing elective open abdominal surgery are affected and methods to reduce surgical site infection
rates warrant further investigation and evaluation in randomized controlled trials.
Methods/design: To investigate whether the application of a circular plastic wound protector reduces the rate of
surgical site infections in general and visceral surgical patients that undergo midline or transverse laparotomy by
50%. BaFO is a randomized, controlled, patient-blinded and observer-blinded multicenter clinical trial with two
parallel surgical groups. The primary outcome measure will be the rate of surgical site infections within 45 days
postoperative assessed according to the definition of the Center for Disease Control. Statistical analysis of the
primary endpoint will be based on the intention-to-treat population. The global level of significance is set at 5%
(2 sided) and sample size (n = 258 per group) is determined to assure a power of 80% with a planned interim
analysis for the primary endpoint after the inclusion of 340 patients.
Discussion: The BaFO trial will explore if the rate of surgical site infections can be reduced by a single, simple,
inexpensive intervention in patients undergoing open elective abdominal surgery. Its pragmatic design guarantees
high external validity and clinical relevance.
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Figure 1 Schematic drawing of the wound edge protectors
used in the BaFO trial. The protector consists of an impervious
drape that covers the abdomen of the patient and is fixed to the
skin with the help of adhesive tapes. It has a standardized size of
90 × 90 cm. The hole in the middle is connected to a flexible plastic
ring that fits into the abdominal wound and protects the wound
edges (skin, subcutaneous tissue, fascia and muscle) from contact
with viscera, visceral contents and gloves, while allowing for
visualization of the wound edges.
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Rationale for the trial
Postoperative surgical site infections (SSIs) are one of
the most frequent surgical complications and a major
cause of postoperative morbidity, prolongation of hos-
pital stay, healthcare costs and even mortality. An esti-
mated 300,000 to 500,000 SSIs occur in the USA
annually [1-4]. In Germany SSIs are the third most fre-
quent cause of nosocomial infections and account for
approximately 15% of the 400,000 to 600,000 nosocomial
infections per year (60,000 to 90,000 cases) according
to data from the Robert-Koch Institute (RKI) and the
German Nationales Referenzzentrum für Surveillance
von Nosokomialen Infektionen (NRZ) [5,6]. Data from
the German Krankenhaus Infektions-Surveillance-System
(KISS) estimate an even higher number of approximately
128,000 SSIs annually [6]. Furthermore, an estimated
7,500 to 15,000 patients die every year in Germany due
to nosocomial infections [7,8].
Despite the implementation of preventive measures
such as preoperative antibiotic prophylaxis [9-12] and
antiseptic skin cleansing [9,13], SSI rates in prospective
trials with adequate follow-up and standardized SSI def-
inition in abdominal surgical patients remain high and
vary from 14% to 32% [14-17]. Applying the SSI criteria
of the Center for Disease Control (CDC) [9], which dif-
ferentiate between superficial, deep and organ-space SSIs
at postoperative day 30, Darouiche et al. reported an
overall SSI rate of 16.1% in the control group (povidone-
iodine skin preparation) of their randomized controlled
trial (RCT) in patients with clean-contaminated abdom-
inal surgery [18]. Seiler et al. reported similar numbers
in a randomized multicenter trial comparing three dif-
ferent techniques of abdominal wall closure in abdom-
inal surgical patients with SSI rates varying from 13% to
19% [19]. SSI rates following colorectal surgery seem to
be even higher as was shown by Bennett-Guerrero and
colleagues, who reported an overall SSI rate of 21% in
the control group (and 30% in the intervention group)
of their prospective multicenter RCT comparing the
application of a gentamicin-collagen sponge versus no
intervention in colorectal patients [20]. National data
from the USA support these numbers [21].
Multiple studies have shown an increase in the mean
length of hospital stay by 6 to 24 days if SSIs occur
[4,22-25]. The resulting direct costs have to be added to
the indirect costs such as loss of workforce or insurance
payments resulting in substantial expenses for the
healthcare system [26-28].
The most frequent pathogens causing postoperative
SSIs in general and abdominal surgical patients are
endogenous pathogens from the skin or gastrointes-
tinal tract (KISS data 2005 to 2008, [29]). This im-
plies that adequate protection of the surgical site bywound edge protectors might reduce the rate of post-
operative SSIs.
Previous trials
Several previous trials have investigated the effect of
wound edge protectors on SSI rates in abdominal sur-
gery and report mixed results. While some found benefi-
cial effects [30-33] others reported no benefit [34-36].
Similarly, a randomized trial in 2011 in which wound
protectors were introduced together with other measures
as a bundle to reduce SSIs did not show a benefit [37].
The diverging results may be explained by trial
design, since the mentioned trials were either performed
in a single institution setting, had small sample sizes,
lacked adequate blinding, standardization or used varying
definitions of outcome variables (SSI definitions). Large
multicenter randomized trials comparing the use of a
wound edge protector with standard intervention (sterile
towels) under standardized conditions and with defined
outcome variable (CDC definition of SSIs) are lacking.
It is important to point out that BaFO will apply a
circular plastic wound edge protector covering the
whole width of the wound (skin, subcutaneous tissue,
fascia and muscle; Figure 1) not other forms of surgical
draping such as adhesive incise drapes for which benefi-
cial [38,39] as well as non-beneficial results [40,41] have
Table 1 Exclusion criteria of the BaFO trial
No. Exclusion criteria
1 ASA grade >3
2 Pregnant or lactating women
3 Midline or transverse laparotomy within the last 60 days prior to
trial intervention
4 Planned relaparotomy within 30 days after trial intervention
5 Contaminated operations according to CDC definition [9]
6 Small abdominal operations without planned transverse or midline
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intervention compared to no adhesive drapes found no
evidence that iodine impregnated adhesive drapes reduce
the SSI rate (relative risk 1.03, 95% confidence interval
0.064 to 1.66, P= 0.89) [42]. Interestingly, when the
authors of the same meta analysis compared the use of
non-impregnated adhesive drapes to no drape usage,
they found the SSI rate significantly increased in the
drape group (relative risk 1.23, 95% confidence interval
1.02 to 1.48, P= 0.03).laparotomy (for example, appendectomy)
7 Concurrent abdominal wall infections
8 Severe immunosuppression, for example after: organ or bone
marrow transplantation, concurrent steroid treatment with >10 mg
prednisone daily (or an equivalent dose of any other steroid),
concurrent infliximab treatment or treatment with an equivalent
immunosuppressive substance, or chemotherapy within the last
2 weeks prior to trial intervention
9 Severe preoperative neutropenia (≤0.5 × 109 cells/l)
10 Liver cirrhosis; Child-Pugh B or C [43]
ASA = American Society of Anesthesiologists; CDC = Centers for Disease
Control and Prevention.Objective
BaFO aims to investigate whether the application of a
circular plastic wound edge protector (Figure 1) reduces
the rate of SSIs (within 45 days postoperatively) in
abdominal surgical patients that undergo elective mid-
line or transverse laparotomy by 50% (from 16% to 8%).
As a secondary endpoint the difference in intraoperative
core body temperature between the two study groups
will be evaluated.Trial sites
The BaFO trial will be performed at 15 sites of the Trial
Network (CHIR-Net) of the German Surgical Society
(Deutsche Gesellschaft für Chirurgie (DGCH)). Most of
these sites have participated in previous randomized
controlled trials and all centers were adequately trained
and prepared according to International Conference on
Harmonisation of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use (ICH)-good
clinical practice (GCP) rules for participation in this
trial. CHIR-Net is funded by the German Ministry of
Research and Education (Bundesministerium für Bildung
und Forschung (BMBF); see funding information below).Methods/design
Trial population and eligibility criteria
All general and abdominal surgical patients scheduled
for elective open abdominal surgery requiring a median
or transverse laparotomy will be eligible, given their
ability to understand the extent and nature of the BaFO
trial as well as their written informed consent. Patients
participating in the BaFO trial must be 18 years of age
or older, and the planned operation should be classified
as clean or clean-contaminated as per the CDC defin-
ition [9]. Exclusion criteria are listed in Table 1.Sample size
A total of 258 patients will be analyzed per group. Given
an estimated drop out rate of approximately 15%,
600 patients will be randomized to 1 of the 2 treat-
ment arms.Type of trial
Randomized, controlled, observer and patient blinded mul-
ticenter surgical trial with two parallel comparison groups.
Recruitment and trial timeline
A total of 15 centers of general and abdominal surgery
in Germany will participate in this trial. The centers
vary from university hospitals to community hospitals
and include certified centers for colorectal surgery
(Darmzentren). All centers are members of the Trial
Network (CHIR-Net) of the German Surgical Society.
Physicians or nurses involved in the trial have been
trained in ICH-GCP prior to initiation of the trial. Fur-
thermore, all centers and participants were specifically
instructed in study-specific procedures prior to the start
of the trial. The centers will be supported by an ICH-
GCP qualified flying study nurse from the CHIR-Net
Surgical Regional Centre Munich to ensure protocol
conforming data acquisition and trial interventions.
Stratification according to center will be performed and
all centers must recruit a minimum of 15 patients.
The duration of the recruitment phase is expected to
be 30 months. The last follow-up will be performed a
maximum of 45 days after the last patient underwent
the trial intervention. Hence, the total duration of the
trial is expected to be no longer than 32 months. The
study flow is outlined in Figure 2.
Randomization and blinding
Randomization and blinding will be performed with the
help of sealed, opaque, individually numbered envelopes,
restricted to choosing one at a time. The envelopes
Screening: 





to be allocated to trial
n = 600
n = 50 not compliant
n = 50 no informed consent
Visit 2
Randomization: 
between or at visit 1 - day of operation
sterile surgical dressings
n = 300





 of core body temperature
Surgery:
intervention and measurement
 of core body temperature
blinded SSI assessment:
at postOP day 
2, 4, 6, 8, 10-14
Visit 4 - 8
blinded SSI assessment:
at postOP day 
2, 4, 6, 8, 10-14
blinded SSI assessment:
at postOP day 
30-45
blinded SSI assessment:
at postOP day 
30-45
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Figure 2 Flow chart of the BaFO trial. F/U = follow-up; postop day = postoperative day; R = randomization; SSI = surgical site infection.
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group allocation and the randomization number. Both
will be prefabricated by a biostatistician of the Tech-
nische Universität München (TUM; Munich, Germany).
Randomization (visit 2, see Figure 2) will be performed
after inclusion of the patient in the trial (informedconsent, visit 1) or in the period between inclusion and
the trial intervention (day of surgery) or at the day of
surgery (visit 3). Randomization will be performed strati-
fied by center. To assure balanced group sizes in the
course of the accrual, a blockwise randomization is
applied. Basic characteristics of the patient and day of
















days 10 to 14)
Visit 9 (postop









Blood samplinga X Xb
Randomization X
Temperature measurement X
Wound documentation X X X X X X
Mibi swabc X X X X X X
Measurement of wound diameter X
aBlood sampling: Serum: sodium, potassium, creatinin, C-reactive protein, total protein, blood urea nitrogen, glutamic-pyruvic transaminase, glutamic-oxaloacetic transaminase, γ-glutamyl transpeptidase,
pseudocholinesterase, alkaline phosphatase, glucose; blood count: leucocytes, erythrocytes, hemoglobin, hematocrit, mean corpuscular hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin
concentration, platelets; Coagulation: quick (international normalized ratio), prothrombin time.
bOne blood sampling between postoperative day 4 to 8 (visits 5 to 7).
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ization sheets. Subsequently, randomization sheets must
be dated, signed and stored away from the patient
records, the trial documents and the investigator site file
to ensure blinding. Patients, outcome assessors and the
trial statistician will be blinded for the trial intervention.
The outcome assessor (postoperative SSIs) will therefore
neither be part of the surgical team that performs the
trial intervention nor have access to the randomization
sheets. Patients will be blinded since they are under
general anesthesia during the operation and therefore
will not be aware which intervention is used during
the operation.
Interventions
Experimental intervention: all elective general or abdom-
inal surgical patients undergoing a midline or transverse
laparotomy for any cause will have their surgical inci-
sions covered with a circular sterile plastic wound edge
protector during the operation (see Figure 1).
Control intervention: draping of the surgical incision
will be performed with standard sterile surgical dressings.
The schedule of trial interventions is presented in
Table 2.
Risks
No additional risks for study patients are anticipated,
since the application of a circular sterile plastic wound
edge protector represents a clinically established stand-
ard method. The wound edge protector used in BaFO is
CE certified (3 M Steri-Drape Wound Edge Protector,
3 M, St. Paul, MN, USA). All surgical procedures carried
out within BaFO are not affected by the trial.
Outcomes
Primary efficacy endpoint of the BaFO trial is the rate of
SSIs according to Center for Disease Control (CDC) cri-
teria, which constitutes the internationally accepted
standard definition within 45 days postoperatively [9].
Secondary outcome measure is the intraoperative core
body temperature measured at the beginning, in the
middle and at the end of the operation via nasal, rectal,
transurethral or central venous probes. Temperature as
well as the modality of measurement will be recorded.
Data management
All required information collected during the trial is
entered in the case record form (CRF) by the investiga-
tor or a designated representative. Documentation is
expected to be completed as soon as possible after
the information has been collected. The investigator is
responsible for the accuracy of the documentation and
must ensure that all entries can be verified by source
data. An explanation must be given for all missing data.Corrections in the CRF must be signed, dated and leave
the corrected entry visible. The completed CRF must be
reviewed, signed and dated by the investigator named in
the trial protocol or by a designated subinvestigator. After
keeping a copy at the trial center, the original CRF is sent
in a sealed envelope by certified mail to the Centre for
Data Management at the Münchner Studienzentrum
(MSZ; member of the Network of Coordinating Centres
for Clinical Trials (KKS Network) at the Technische Uni-
versität München, Munich, Germany). Double data entry
is performed by data management according to standard
operating procedures predefined in the data management
plan to ensure correct transfer of data from the CRF to the
database (hardware: Windows Server NT 2003 (Microsoft,
Redmond, WA, USA); software: MACRO™ V.3, Microsoft
SQL Database (Microsoft, Redmond, WA, USA); browser:
Microsoft Internet Explorer V.6 or higher (Microsoft, Red-
mond, WA, USA)). Completeness, validity and plausibility
of data are examined by validating programs as well as in-
dividual inspection and queries are generated accordingly
which need to be clarified by the investigator or designated
subinvestigator. At the end of the trial the principal investi-
gator will retain the original CRFs.
Monitoring
Monitoring of the trial data will be performed by an
independent institution experienced in the monitoring of
surgical trials (KKS Network) at the TUM (Münchner
Studienzentrum). Monitoring will be carried out in
accordance with ICH-GCP guidelines [44] and standard
operating procedures of the MSZ to ensure patients´
safety and integrity of the clinical data, for example, pri-
mary outcome measure in adherence to study protocol.
All trial sites are activated with an initiation visit by the
monitor or CHIR-Net coordinator, who will hand out and
explain the investigator site file, discuss relevant issues
and train trial personnel in study-specific interventions.
Regular contact by phone or email with all participating
centers will enable the CHIR-Net Coordinator and the
monitor to control the study progression, adherence to
the study protocol, and to discuss problems related to the
study. Regular on-site monitoring visits are planned for
all sites. Investigators must allow the monitor to look at
all essential documents, support the monitor during visits
and answer queries. All monitoring procedures will be
predefined in a trial-specific monitoring manual. In
addition, a GCP-trained flying study nurse employed by
the CHIR-Net regional center Munich will assist the trial
sites with documentation and data collection if needed.
Furthermore, close-out visits are planned for each center.
Safety evaluation and reporting of adverse events
Occurrence of the primary endpoint is assessed as end-
point only (not as adverse event).
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operation and will therefore not be classified as adverse
events: pain, nausea, vomiting, urinary tract infection,
hyper/hypotension, imbalances of blood sugar or elec-
trolytes and other lab values out of range, if they do
not exceed grade 3 to 4 in the Common Terminology
Criteria for Adverse Events version 3.0 [45]. Assessment
will be performed by the investigator or the designated
subinvestigator.
From the day the patient has signed informed consent
until the regular end of the trial (visit 9) or until prema-
ture withdrawal of the patient, all serious adverse events
(SAEs) will be documented on a ‘serious adverse events
form’ available in the investigator site file. An SAE will
be defined as an event, that results in death, is immediately
life threatening, requires or prolongs hospitalization or
results in persistent or clinically important disability or in-
capacity as judged by the investigator or designated subin-
vestigator. SAEs will be classified to intensity (mild,
moderate, severe), outcome (ongoing, recovered com-
pletely, recovered with sequelae, death, unknown) and
causality (unrelated; possibly, probably or definitely related
to trial intervention; not assessable). The assessment is
based on clinical findings and needs to be performed by
the investigator or designated subinvestigator in the par-
ticipating trial centers. SAEs will have to be reported
within 7 days after becoming known.
Statistical methods
Sample size calculation
Sample size calculation is based on the primary end
point of surgical site infections within 45 days post oper-
ation according to the CDC classification [9] and was
conducted by using nQuery Advisor software version 7.0
(Statistical Solutions Ltd, Cork, Ireland). Based on the
assumption that the percentage of patients developing
postoperative wound infections in a mixed surgical
population undergoing midline or transverse laparotomy
is approximately 16% for the standard group (control
group, see Background) and can be reduced to 8% in the
experimental intervention arm, a group sample size of
258 patients would need to be compared by the χ2 test,
to achieve 80% power in detecting this difference in SSI
rate at a 2-sided level of significance of 5%. Analysis of
the primary efficacy endpoint will be based on a χ2 and
not based on a random effects model, which would
assume different underlying effects within the centers.
However a generalized linear mixed effect model (logit
link regression) will be fitted to the data in terms of a
supportive sensitivity analysis that allows for assessment
of the primary efficacy endpoint under consideration of
random center effects. Under the assumption of a drop-
out rate of up to 15%, a total of 600 patients would need
to be enrolled in the study. Due to the broad inclusioncriteria, the limited number of exclusion criteria, the
limited time frame as well as the comprehensible nature
of the trial, no more than 200 patients are expected to
be screening failures, which brings the total number of
patients that need to be screened for eligibility to 800
(Figure 2).
Based on the multicenter trail design, stratification
according to recruiting center will be used [46]. Each
participating center will have to enroll a minimum of 15
patients. Centers with fewer than 15 patients will be
excluded from the primary efficacy analysis. Therefore,
recruitment will be continued until enough centers lead
to the required total sample size by each enrolling a suf-
ficient number of patients.
Analysis
The primary analysis will be conducted according to the
intention-to-treat (ITT) principle, that is, all included
patients will be analyzed as randomized. Patients with
missing primary outcome data will be considered as non-
SSI cases if they belong to the control group and as SSI
cases if they were randomized to the innovative treatment
arm. For purpose of sensitivity analyses, per protocol
and complete case analyses of the primary endpoint will
be conducted and further appropriate and less conserva-
tive missing-value replacement strategies such as multiple
conditional imputation [47] will be employed.
A planned interim analysis will be performed after re-
cruitment and follow-up of 340 patients (two-thirds of
the planned total). Due to this intended interim analysis,
global α error adjustment is performed by the method of
O’Brien and Fleming [48]. Therefore, evaluation of the
primary efficacy endpoint will be conducted at a 0.005
level of significance (two sided) in the interim analysis
and at a 0.048 level of significance (two sided) in the
final statistical analysis.
Prespecified subgroup analyses or treatment group
comparisons will be performed for: rate of superficial
postoperative SSIs (according to CDC classification); rate
of deep postoperative SSIs (according to CDC classifica-
tion); rate of postoperative SSIs of organ space (accord-
ing to CDC classification); rate of postoperative SSIs
(total/superficial/deep/organ space) stratified by the Na-
tional Nosocomial Infection Surveillance (NNIS) risk
score [46]; rate of postoperative SSIs (total/superficial/
deep/organ space) stratified by colorectal and non-
colorectal operations.
Secondary analyses will be conducted in an explorative
manner. Kaplan-Meier analysis and Cox regression
analyses will be employed for analyses of time to event
endpoints. The χ2 test will be used to compare frequency
data between intervention groups. As appropriate, the
Student t test, Mann–Whitney U test or analysis of
covariance (ANCOVA) will be employed for group
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intervals will be provided for estimates of relevant ef-
fect sizes.
Safety analysis includes description and comparison
of the frequency of adverse and serious adverse events in
the two intervention groups.
Procedures for the statistical analysis of the primary
and secondary endpoints will be conducted in line with
the ICH-GCP E9 guideline [49]. For the statistical ana-
lysis, SASW software version 9.2 or higher will be used
(SAS Institute Inc., Cary, NC, USA). The statistical ana-
lysis will be performed by a group-allocation-blinded
statistician from the Institute for Medical Statistics and
Epidemiology of the TUM.
Withdrawals
Patients are free to withdraw trial participation at their
own request at any time and without giving reasons for
their decision. Withdrawals will be documented in the
CRF and in the patient´s medical record. Furthermore,
all ongoing SAEs have to be followed-up and documen-
ted until their final outcome can be determined.
Stopping guidelines
The trial can be prematurely closed by the coordinating
investigator in consultation with the responsible biostat-
istician for the following reasons: the planned interim
analysis indicates that rate or severity of SAE/morbidity
in this trial poses a potential health hazard caused by
the trial treatment in one or both of the trial groups;
it appears that patients' enrolment is unsatisfactory
with respect to quality or quantity or data recording is
severely inaccurate or incomplete; external evidence
demanding a termination of the trial.
In case of premature closure, the ethics committee has
to be informed.
Trial organization and administration
Funding
The Trial Network CHIR-Net of the German Surgical
Society (DGCH) is funded by the German Ministry of
Research and Education (Bundesministerium für Bildung
und Forschung (BMBF); 01GH0702). The circular poly-
ethylene wound protector (Steri-Drape Wound Edge Pro-
tector) used in the BaFO trial is provided by 3 M
Infection Prevention Division (3 M Medica, 3 M Deutsch-
land GmbH, Neuss, Germany). No financial support is
given other than the funding by the BMBF mentioned
above (01GH0702). There are no restrictions on publica-
tions and no conflict of interest. The idea for the BaFO
trial was conceived, the trial protocol written and the trial
initiated independent of the any industrial funder. Indus-
trial funders and trial management are independent.Ethics approval
Before the start of the trial, the trial protocol, informed
consent document and any other trial documents were
submitted to the independent ethics committee on 7
June 2010. Ethics approval was granted on 22 June 2010.
A major protocol amendment was submitted to the
ethics committee on 18 November 2010 and was approved
1 December 2010.
Registration
The trial protocol was registered at http://www.clinicaltrials.
gov and was given the number NCT01181206.
Good clinical practice
The procedures set out in this trial protocol, pertaining
to the conduct, evaluation and documentation of this
trial, are designed to ensure that all persons involved in
the trial abide by Good Clinical Practice [44] and the
ethical principles described in the current revision of the
Declaration of Helsinki [50]. The trial will be carried out
in keeping with local legal and regulatory requirements.
Discussion
Postoperative SSIs are among the most frequent sur-
gical complications affecting approximately 14% to 32%
[14-17] of abdominal surgical patients. These numbers
have changed little over the last 20 years despite inter-
nationally accepted recommendations for control of SSIs
(reviewed in [51]). In prospective trials with clear defini-
tions, SSI rates tend to be higher [14,18-20] due to the
fact that a number of SSIs occur late, after discharge of
the patients from the hospital and would thus remain
unnoticed if standardized wound evaluation as well as
adequate follow-up are not applied. Furthermore, even if
superficial SSIs are diagnosed, inadequate follow-up will
result in underestimation of the number of deep or
organ-space SSIs. To standardize reporting of SSI rates,
the CDC has issued an internationally accepted defin-
ition of SSIs. According to this definition SSIs are
grouped into superficial, deep and organ-space SSIs
(Table 3).
The most frequent pathogens causing postoperative
SSIs in general surgical patients are Staphylococcus aur-
eus, Escherichia coli and Enterococcus spp. Similarly, in
abdominal surgical patients E. coli, Enterococcus spp,
Enterobacter spp and S. aureus are the most frequent
pathogens (KISS data 2005 to 2008, [29]). These data in-
dicate that endogenous infections from the patients´
skin or the gastrointestinal tract account for most SSIs
and that a high number of SSIs might be prevented by
adequate coverage of the incisional wound edges during
surgical procedures. Wound edge protectors such as the
one used in the BaFO trial do not only prevent displace-
ment of skin pathogens into the surgical site such as




1 Infection occurs within 30 days after the operation AND
2 Infection involves only skin or subcutaneous tissue of the incision AND
3 At least one of the following:
A. Purulent drainage, with or without laboratory confirmation, from the superficial incision
B. Organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision
C. At least one of the following signs or symptoms of infection: pain or tenderness, localized swelling,
redness, or heat and superficial incision is deliberately opened by surgeon, unless incision is culture negative
D. Diagnosis of superficial incisional SSI by the surgeon or attending physician
Deep incisional SSI:
1 Infection occurs within 30 days after the operation AND
2 Infection involves deep soft tissues (for example, fascial and muscle layers) of the incision AND
3 At least one of the following:
A. Purulent drainage from the deep incision but not from the organ/space component of the surgical site
B. A deep incision spontaneously dehisces or is deliberately opened by a surgeon when the patient
has at least one of the following signs or symptoms: fever (>38°C), localized pain, or tenderness, unless site is culture negative
C. An abscess or other evidence of infection involving the deep incision is found on direct examination, during reoperation,
or by histopathologic or radiologic examination
D. Diagnosis of a deep incisional SSI by a surgeon or attending physician
Notes: (1) report infection that involves both superficial and deep incision sites as deep incisional SSI; (2) report an organ/space
SSI that drains through the incision as a deep incisional SSI
Organ/space SSI:
1 Infection occurs within 30 after the operation AND
2 Infection involves any part of the anatomy (for example, organs or spaces), other than the incision, which was opened or
manipulated during an operation AND
3 At least one of the following:
A. Purulent drainage from a drain that is placed through a stab wounda into the organ/space
B. Organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space
C. An abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation,
or by histopathologic or radiologic examination
D. Diagnosis of an organ/space SSI by a surgeon or attending physician
SSIs are categorized into superficial, deep and organ-space infections.
aIf the area around a stab wound becomes infected, it is not an SSI. It is considered a skin or soft tissue infection, depending on its depth.
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skin, subcutaneous tissue, fascia and muscle from spill-
age of abdominal content during the surgical procedure.
In addition, wound edge protectors cover the entire
abdomen during the surgical procedure and thus
have the theoretical benefit of improved temperature
control and prevention of intraoperative hypothermia,
a factor associated with SSIs in several studies [52,53].
We have incorporated this question into the BaFO trial
by measuring the intraoperative core body tempera-
ture in both groups and analyze the differences as sec-
ondary endpoint.
However, wound edge protectors have not yet been
rigorously tested in multicenter randomized controlled
trials, since the studies available today are either single-center trials, lack clear SSI definitions/endpoints, or
only include a small number of patients. Even in the
trials available mixed results have been reported. A
recent single center trial in elective colorectal patients
reported a reduction of SSI rates from 22.7% to 4.7%
[30]. Similarly, in a non-randomized single-center pro-
spective trial with 221 patients reported a reduction
in SSI rates only for patients undergoing colorectal
surgery. Interesting only superficial SSI rates were
reduced while rates of organ-space infections remained
unchanged [31]. A randomized trial with 352 patients
at 2 institutions found a reduction of SSIs from 22.6%
to 10.5% with the application of a wound-edge protector
in patients with clean/contaminated or contaminated
wounds [32]. However, in a report from Psaila et al.
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abdominal surgery [34]. Similarly, a study by Kercher
et al. reported no benefit of wound protectors in
patients undergoing laparoscopic-assisted colon surgery
[35], a result that was confirmed for open colorectal sur-
gery by Nyström et al. [36]. Furthermore, several of
these trials were underpowered. Taken together these
conflicting results disallow a definitive answer whether
wound-edge protectors constitute a reasonable approach
to reduce SSI rates in general and abdominal surgery.
Hence, sufficient pilot data are available to justify
the conduct of a prospective multicenter randomized
patient-blinded and observer-blinded trial. Since fur-
ther single center studies would not increase the exter-
nal validity (generalizability) a multicenter approach was
chosen and the trial was initiated within the Trial Net-
work of the German Surgical Society (CHIR-Net). To
further increase external validity broad inclusion criteria
and few exclusion criteria are applied allowing for the
screening and recruitment of many elective open general
and abdominal surgical cases in the participating hospi-
tals. Hospitals of different care levels participate in this
trial together underlining the pragmatic approach of the
trial. For many participating surgical departments SSIs
represent the most frequent postoperative complication
and thus a pressing surgical question that remains to be
solved. To ensure data quality members of all participat-
ing centers are trained in GCP guidelines, trial interven-
tion, documentation and blinding. In addition, internal
validity is ensured by patient-blinding and observer-
blinding, application of definite endpoints (SSI defini-
tion by the CDC) and complete outcome reporting and
follow-up. Applying high methodological standards the
results of the trial should help to improve surgical treat-
ment of patients.
Trial status
As of 29 February 2012 a total of 323 patients had been
recruited to the trial.
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